Quarterly ResultAug 5, 2026, 04:21 PM
ADMA Biologics Q2 Revenue $124.4M, Net Income $37.8M; Reiterates FY26 Guidance
AI Summary
ADMA Biologics reported strong second quarter 2026 financial results, with total revenue increasing 2% year-over-year to $124.4 million, driven by a 24% surge in ASCENIV revenue to $102.9 million. GAAP net income rose 11% to $37.8 million, and Adjusted EBITDA grew 22% to $61.8 million. The company reiterated its full-year 2026 financial guidance, highlighting accelerating ASCENIV demand, stabilizing BIVIGAM utilization, and ongoing progress in its SG-001 development program. ADMA also continued its share repurchase program, buying back 7.1 million shares in the quarter.
Key Highlights
- Q2 2026 Total Revenue reached $124.4 million, a 2% increase year-over-year.
- ASCENIV revenue grew 24% year-over-year to $102.9 million in Q2 2026.
- GAAP Net Income for Q2 2026 was $37.8 million, up 11% year-over-year.
- Adjusted EBITDA increased 22% year-over-year to $61.8 million in Q2 2026.
- GAAP Basic EPS was $0.17 for Q2 2026, representing 17% year-over-year growth.
- The company reiterated FY2026 total revenue guidance of $530 million to $560 million.
- ADMA repurchased approximately 7.1 million shares in Q2, totaling 13.8 million YTD.
- Gross margin expanded to 69% in Q2 2026, up from 55% in the prior-year period.
Price Impact
More from ADMA